Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma

NCT01701479 is registered in ClinicalTrials.gov with St. Anna Kinderkrebsforschung as lead sponsor.

NCT NCT01701479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01701479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma
Lead sponsor
St. Anna Kinderkrebsforschung
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2012
Completion date
December 31, 2020
Enrollment
288 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma